Sec Form 4 Filing - Wang Xiaodong @ BeOne Medicines Ltd. - 2025-06-10

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Wang Xiaodong 2. Issuer Name and Ticker or Trading Symbol BeOne Medicines Ltd. [ ONC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) X __ Other (specify below) Chair, Scientific Advisory Brd (Last) (First) (Middle) C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 06/10/2025 (Street) BASEL, V84051 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares ( 1 ) 06/10/2025 A 98,696 A $ 0 5,180,861 D Ordinary Shares 1,025,063 I See Footnote ( 2 ) Ordinary Shares 3,953,100 I See Footnote ( 3 ) Ordinary Shares 50 I See Footnote ( 4 ) American Depositary Shares ( 5 ) 06/10/2025 M 41,760 A $ 6.5 41,760 D American Depositary Shares ( 5 ) 06/10/2025 S( 6 ) 2,901 D $ 261.2041 ( 7 ) 38,859 D American Depositary Shares ( 5 ) 06/10/2025 S( 6 ) 15,878 D $ 262.2032 ( 8 ) 22,981 D American Depositary Shares ( 5 ) 06/10/2025 S( 6 ) 16,094 D $ 263.1727 ( 9 ) 6,887 D American Depositary Shares ( 5 ) 06/10/2025 S( 6 ) 6,787 D $ 264.0804 ( 10 ) 100 D American Depositary Shares ( 5 ) 06/10/2025 S( 6 ) 100 D $ 264.85 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Share Option (Right to Buy) $ 20.26 ( 11 ) 06/10/2025 A 185,796 ( 11 ) ( 12 ) 06/09/2035 Ordinary Shares 185,796 $ 0 185,796 D Share Option (Right to Buy) $ 0.5 06/10/2025 M 542,880 ( 13 ) 07/19/2025 Ordinary Shares 542,880 $ 0 7 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Wang Xiaodong C/O BEONE MEDICINES I GMBH AESCHENGRABEN 27, 21ST FLOOR BASEL, V84051 X Chair, Scientific Advisory Brd Signatures /s/ Qing Nian, as Attorney-in-Fact 06/12/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. ( 2 )These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership. ( 3 )These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership. ( 4 )These securities are held by the spouse of the Reporting Person. ( 5 )Each American Depositary Share represents 13 Ordinary Shares. ( 6 )The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024. ( 7 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.66 to $261.64, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. ( 8 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.66 to $262.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. ( 9 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.66 to $263.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. ( 10 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.66 to $264.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. ( 11 )The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. ( 12 )These securities vest over a four-year period as follows: 25% on the first anniversary of June 10, 2025 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. ( 13 )These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.